Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Rituximab Coverage & Prior Auth | Open…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0109

    Rituximab (Riabni, Rituxan, Ruxience, Truxima) Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0109 alerts

    Get alerted when Policy IC-0109 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, length of authorization, dosing limits, and renewal rules for rituximab (Riabni, Rituxan, Ruxience, Truxima) for oncology and non-oncology indications for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyRituximab (Riabni, Rituxan, Ruxience, Truxima) Coverage Criteria
    Policy CodePolicy IC-0109
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with an eligible Appendix 1 ICD-10 diagnosis and document prior trials, dosing regimen, and HBV screening per policy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsstandard initial PA validity
    180 daysrenewal interval
    100-780HCPCS unit range
    Requiredbiosimilar trial requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required
    HBV screening

    Coverage and Medical Necessity Criteria

    Authorization length and renewal criteria

    Authorization validity and renewal rules for oncology and non-oncology indications

    Oncology initial and renewal: Initial prior authorization validity for oncology indications: 6 months (180 days). Renewal: may be renewed every 6 months (180 days) for up to a maximum of 2 years unless otherwise specified.

    Certain oncology indications have specific non-renewable or alternate renewal rules as listed.

    Oncology non-renewable or alternate renewal: Prior authorization validity may NOT be renewed for specified indications (examples include: Pediatric B‑Cell Acute Leukemia induction/consolidation; Pediatric Aggressive Mature B‑Cell Lymphomas induction/consolidation; Pediatric Hodgkin Lymphoma; KSHV‑Associated Inflammatory Cytokine Syndrome; Management of immune checkpoint inhibitor‑related toxicities [excluding Bullous Dermatitis/Bullous Pemphigoid]; Hematopoietic Cell Transplantation; Transplant‑Associated TMA; certain Post‑Transplant Lymphoproliferative Disorder prevention scenarios). Some oncology uses have alternate renewal allowances (e.g., select adult B‑cell lymphoma regimens may be renewed until progression; Adult ALL renewed up to 18 doses; hairy cell leukemia and cGVHD up to 12 doses; bullous dermatitis/pemphigoid related to ICI up to 18 months / 4 doses).

    See policy for the full list and indication‑specific exceptions (renewal durations vary).

    Non‑oncology initial and renewal: Initial prior authorization validity for non‑oncology indications: 6 months (180 days) unless otherwise specified. Initial validity is 12 months (365 days) for Pemphigus Vulgaris, Systemic Lupus Erythematosus, and Lupus Nephritis. Renewal: may be renewed every 6 months (180 days) thereafter unless otherwise specified; some non‑oncology indications may NOT be renewed except for relapse scenarios (e.g., Pediatric Idiopathic Nephrotic Syndrome may be renewed only for relapses; Complications of Transplanted Solid Organ and Wiskott‑Aldrich Syndrome are listed as non‑renewable).

    Indication‑specific renewal rules and exceptions apply.

    Dosing limits and regimens

    Covered dosing regimens when meeting medical necessity for the listed indications

    CLL/SLL dosing limits: Initial: 100 billable units x1 dose, then 130 billable units every 7 days x11 doses. Renewal: 130 billable units every 8 weeks.

    (CLL/SLL per HCPCS unit guidance)

    ALL dosing limits: 100 billable units twice weekly for initial therapy.

    (Acute lymphoblastic leukemia dosing)

    Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Initial: 100 billable units every 7 days x12 doses. Renewal: 400 billable units every 6 months.
    B‑Cell Lymphoma dosing: Initial: 100 billable units every 7 days x8 doses in a 6‑month period. Renewal: 800 billable units every 168 days.

    Initial Authorization / Universal Criteria

    Universal prior authorization and safety criteria applicable to initial approvals

    Universal PA prerequisites: Member must have a contraindication, intolerance, or failure to Riabni®, Ruxience®, AND Truxima® prior to consideration of another rituximab product; AND member is ≥18 years of age unless otherwise specified; AND member does not have a severe, active infection; AND member has been screened for hepatitis B (HBsAg and anti‑HBc) prior to initiating therapy and will be monitored for HBV reactivation if prior/current infection; AND provider will confirm the member has not received a live vaccine within 28 days prior to starting treatment and will avoid live vaccines during therapy.

    Universal initial criteria and safety screening requirements.

    Indication-specific Coverage Statements

    Indication-specific coverage statements (representative selection from document segment). Covered when criteria shown for each indication are met:

    Oncology — CD20 expression requirement: For most oncology indications the member is CD20 antigen expression positive (exclusions apply for cGVHD, HCT, TA‑TMA, KSHV‑Associated syndrome, and ICI‑related toxicities as noted in policy).

    Oncology CD20 positivity requirement.

    Pediatric Mature B‑Cell Acute Leukemia: Member is ≥6 months of age AND rituximab is used in combination with chemotherapy for previously untreated disease.

    Pediatric B‑AL criteria.

    CNS cancers (PCNSL/leptomeningeal): Leptomeningeal metastases from lymphoma: intrathecal or intraventricular administration OR primary CNS lymphoma used for induction/relapse with IV single agent or combination regimens; consolidation monthly maintenance allowed in CR/CRu.

    Intrathecal/intraventricular route noted; interchangeability not established for intra‑CSF routes.

    Pediatric Hodgkin Lymphoma

    Covered when ALL of the following are met

    Pediatric Hodgkin Lymphoma criteria: Member is ≤ 18 years of age (AYA applicability up to age 39 noted) AND member has nodular lymphocyte‑predominant disease AND rituximab is used in combination with CVbP (cyclophosphamide, vinblastine, prednisolone) AND used as primary treatment for stage IA or IIA disease (incomplete resection and non‑bulky disease).

    AYA applicability up to age 39 noted in policy.

    Kaposi Sarcoma / KICS

    Covered when ANY of the following are met

    Kaposi Sarcoma/KICS criteria: Used as systemic therapy in combination with liposomal doxorubicin; OR used as add‑on therapy to alternative Kaposi sarcoma‑directed systemic therapies.

    KSHV‑Associated Inflammatory Cytokine Syndrome (KICS) uses included.

    Chronic Graft-Versus-Host Disease (cGVHD)

    Covered when ALL of the following are met

    cGVHD criteria: Member is post‑allogeneic hematopoietic cell transplant (generally ≥3 months) AND used as additional therapy in combination with systemic corticosteroids AND member has no response (steroid‑refractory) to first‑line therapy options.

    Hematopoietic Cell Transplantation (conditioning)

    Covered when the following is met

    HCT conditioning: Used as conditioning for allogeneic transplant as part of a non‑myeloablative regimen in combination with cyclophosphamide and fludarabine.

    Transplant Associated-Thrombotic Microangiopathy (TA-TMA)

    Covered when ALL of the following are met

    TA‑TMA baseline criteria: Member is post‑hematopoietic stem cell transplant (HSCT) AND alternative diagnoses have been excluded (e.g., TTP, Coombs‑positive hemolysis, medication toxicity, infection, DIC, GVHD) AND member has high‑risk disease defined by at least one listed high‑risk feature.
    TA‑TMA high‑risk features: Random urine protein to creatinine ratio (rUPCR) ≥ 1; OR elevated serum sC5b‑9 > upper limit of normal; OR LDH ≥ 2 × ULN; OR concurrent grade II–IV acute GVHD; OR concurrent infections (bacterial or viral); OR clinical evidence of TA‑TMA‑related organ dysfunction (excluding KDIGO stage I AKI defined as serum creatinine 1.5–1.9× baseline).rUPCR >= 1; LDH >= 2 x ULN

    No minimum age requirement for this indication.

    Immune Checkpoint Inhibitor-Related Toxicities

    Covered when specific immunotherapy‑related severe toxicities and prior steroid/investigational therapy criteria are met

    ICI encephalitis: Member receiving an immune checkpoint inhibitor AND has encephalitis related to immunotherapy AND is autoimmune‑encephalopathy‑antibody positive OR has limited to no improvement after 7–14 days on high‑dose corticosteroids with or without IVIG.
    Bullous dermatitis/pemphigoid related to ICI: Used as additional therapy for severe (G3) or life‑threatening (G4) bullous dermatitis; OR for biopsy/serology‑confirmed bullous pemphigoid used as additional therapy for moderate (G2) disease.

    Prior steroid trial and refractory criteria apply.

    Hemolytic anemia related to ICI: Used as additional therapy for G3 disease if no response to corticosteroids after 5–7 days OR for G4 disease if no response after 3–5 days.
    Thrombocytopenia related to ICI: Used as additional therapy for G3 or G4 disease if no response to corticosteroids after 12 weeks.

    Non-Oncology Indications (concurrent therapy restriction)

    Covered when the following is met

    No concurrent CD20/biologic/targeted therapy: Member is not on concurrent treatment with another CD20‑directed therapy, biologic agent, or targeted synthetic therapy.

    Concurrent CD20 or other excluded biologic/targeted therapies are not permitted.

    Rheumatoid Arthritis (RA)

    Covered when ALL of the following are met

    RA baseline and prior therapy: Physician has assessed baseline disease severity using an objective tool; member has documented moderate to severe active disease; used in combination with methotrexate unless contraindicated; member tried and failed at least a 3‑month trial with one csDMARD OR is already established on biologic/targeted therapy; previous failure with one or more TNF antagonists; no rituximab in prior 4 months.3‑month trial of csDMARD

    Response metrics required for continuation.

    Pemphigus Vulgaris

    Covered when ALL of the following are met

    Pemphigus diagnostic and severity: Diagnosis confirmed by clinical features and biopsy PLUS positive direct immunofluorescence or autoantibodies by IIF/ELISA; moderate to severe disease by objective tool (e.g., PDAI, PSS, ABSIS); used in combination with glucocorticoids; other causes ruled out.

    Induction and maintenance dosing specified in dosing sections.

    GPA and MPA

    Covered when ALL of the following are met

    GPA/MPA age and use: Member is ≥2 years of age AND used as induction therapy in combination with glucocorticoids OR used as maintenance therapy with or without glucocorticoids.

    Pediatric and adult dosing variations apply.

    Thrombocytopenic Purpura (ITP/Evans)

    Covered when ALL of the following are met

    ITP/Evans baseline criteria: Diagnosis of primary/idiopathic thrombocytopenia or Evans syndrome; prior failure or contraindication to corticosteroids; member at increased bleeding risk indicated by platelet count <30 × 10^9/L (within previous 28 days).platelets < 30,000/mm3

    Thrombotic Thrombocytopenic Purpura (TTP)

    Covered when ALL of the following are met

    TTP baseline criteria: Member has immune‑mediated or acquired TTP with ADAMTS13 deficiency AND used in combination with corticosteroids and therapeutic plasma exchange (TPE) OR used as single‑agent prophylaxis in remission.

    Multiple Sclerosis (relapsing forms)

    Covered when ALL of the following are met

    MS (relapsing forms) criteria: Confirmed diagnosis of MS documented by laboratory report (e.g., MRI) AND diagnosis of a relapsing form of MS (RRMS, active SPMS, or CIS).

    Monitoring and response criteria for continuation specified elsewhere.

    Autoimmune Hemolytic Anemia (AIHA)

    Covered when ANY of the following are met

    AIHA criteria: Warm‑reactive disease refractory to or dependent on glucocorticoids; OR cold agglutinin disease with symptomatic anemia, transfusion‑dependence, and/or disabling circulatory symptoms.

    Systemic Lupus Erythematosus (SLE) without active lupus nephritis

    Covered when ALL of the following are met

    SLE without active LN prior therapy: Active SLE WITHOUT active lupus nephritis AND either tried and had inadequate response to hydroxychloroquine (or intolerance/contraindication) AND tried and had inadequate response to one corticosteroid OR one immunosuppressive agent (or intolerance), OR has FDA‑labeled contraindication to all corticosteroids and immunosuppressives AND is on/continues standard SLE therapy; member does not have severe active CNS lupus; will not use in combination with Lupkynis; combination with other immunomodulators allowed only if PI permits and evidence provided.

    Lupus Nephritis (LN)

    Covered when ALL of the following are met

    Lupus Nephritis criteria: Active lupus nephritis with class III, IV, or V disease confirmed by kidney biopsy AND used with background immunosuppressive LN therapy (e.g., corticosteroids plus mycophenolate, azathioprine, or cyclophosphamide) AND no severe active CNS lupus AND combination therapy rules met or evidence provided.

    Renewal restricted to relapse scenarios per renewal section.

    Myasthenia Gravis (MuSK-antibody positive)

    Covered when ALL of the following are met

    MuSK‑positive myasthenia gravis: Member has MuSK‑antibody positive disease AND is refractory to standard first‑line therapy (e.g., glucocorticoids, azathioprine, mycophenolate).

    Complications of Transplanted Solid Organ

    Covered when ANY of the following are met

    Solid organ transplant complications: Used for suppression of panel reactive anti‑HLA antibodies prior to transplantation; OR used for treatment of antibody‑mediated rejection of solid organ transplantation.

    No minimum age requirement for this indication.

    Myasthenia Gravis (MuSK-positive) - Covered when ALL met

    Myasthenia Gravis (MuSK positive, non‑immunotherapy related)

    Myasthenia Gravis (MuSK): Member has MuSK‑antibody positive disease AND member is refractory to standard first‑line therapy (e.g., glucocorticoids, azathioprine, mycophenolate mofetil, etc.).

    Transplant-related antibody suppression or rejection

    Complications of transplanted solid organ

    Solid organ transplant indications: Used for suppression of panel reactive anti‑HLA antibodies prior to transplantation OR used for treatment of antibody‑mediated rejection of solid organ transplantation.

    No minimum age requirement.

    NMOSD - Covered when EITHER seropositive pathway OR seronegative/unknown pathway criteria met

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    AQP4 seropositive pathway: Member seropositive for AQP4‑IgG antibodies AND member has at least one core clinical characteristic AND alternative diagnoses have been excluded.

    Some core clinical characteristics require both clinical and typical MRI findings.

    AQP4 seronegative/unknown pathway: Member seronegative or unknown AQP4‑IgG status AND member has at least two core clinical characteristics occurring as result of one or more clinical attacks AND at least one core characteristic is acute optic neuritis, acute myelitis, or area postrema syndrome AND fulfillment of typical MRI findings for each area affected AND alternative diagnoses excluded.

    Typical MRI lesion patterns defined in policy.

    Antisynthetase Syndrome-Related ILD - Covered when ALL met

    Antisynthetase Syndrome-Related Interstitial Lung Disease

    Antisynthetase ILD criteria: Member has antisynthetase antibody positive disease (e.g., anti‑Jo‑1, ‑PL‑7, ‑PL‑12, ‑OJ, ‑EJ) AND physician has assessed baseline disease severity with objective measures (baseline glucocorticoid use, PFTs, or chest CT) AND documented severe active disease AND recurrent or progressive disease despite glucocorticoids and/or other immunosuppressives AND will be used in combination with glucocorticoids or other immunosuppressive agents unless contraindicated/intolerant.

    PFT and CT thresholds for improvement/stabilization specified in renewal criteria.

    Primary Membranous Nephropathy - Covered when relevant criteria met

    Idiopathic (Primary) Membranous Nephropathy

    Primary membranous nephropathy initial criteria: Documented idiopathic membranous nephropathy AND secondary causes ruled out AND used as first‑line therapy in members with any of: proteinuria >3.5 g/day with no >50% decrease after 6 months ACEi/ARB; OR eGFR <60 ml/min/1.73m2; OR proteinuria >8 g/day for >6 months; OR serious nephrotic complications; OR used for initial relapse after remission or treatment‑resistance to first‑line therapy.

    Member must have stable eGFR and additional combination rules apply for retreatment scenarios.

    Post‑kidney transplant recurrence: Used for disease recurrence following kidney transplant AND member has proteinuria >1 g/day; AND member has stable eGFR; AND will be used with calcineurin inhibitor if previously treated with rituximab alone.proteinuria >1 g/day

    Pediatric Idiopathic Nephrotic Syndrome - Covered when ALL met

    Pediatric Idiopathic Nephrotic Syndrome (≤12 years)

    Pediatric nephrotic syndrome: Member is 12 years of age or younger AND has symptomatic nephrotic‑range proteinuria and hypoalbuminemia or edema AND diagnosed with FRNS, SDNS, or SRNS as defined AND has failed an adequate trial with at least one other steroid‑sparing agent (e.g., cyclophosphamide, calcineurin inhibitor, mycophenolate mofetil).

    Renewal allowed only for members experiencing a disease relapse per renewal section.

    IgG4-Related Disease - Covered when ALL met

    Covered when ALL of the following are met

    IgG4‑Related Disease criteria: Confirmed diagnosis of IgG4‑RD with other mimics ruled out AND member experienced steroid‑treated flare AND disease refractory to corticosteroids or contraindication/intolerance to corticosteroids AND member at high risk of recurrent flares (disease in ≥2 organs/sites) AND at least one specified organ (e.g., pancreas, bile ducts, orbits, lungs, kidneys, major salivary glands, retroperitoneum, aorta, pachymeninges, sinonasal tract, thyroid) is affected.

    Wiskott-Aldrich Syndrome - Covered for pretransplant/preemptive uses

    Covered when the following is met

    Wiskott‑Aldrich pretransplant/preemptive uses: Used as pretreatment prior to infusion of etuvetidigene autotemcel to deplete autoreactive B‑cells OR used as pre‑emptive treatment for potential EBV‑related lymphoproliferative disorder.

    Indication is for pretransplant/preemptive use.

    Oncology - Continuation criteria

    Oncology indications - renewal/continuation

    Oncology continuation criteria: Member has not exceeded dosing or duration limits AND treatment response or stabilization is documented (e.g., CBC, bone marrow cytogenetics, QPCR, FISH for ALL; tumor stabilization or decrease in tumor size/spread for other oncology indications).

    Some oncology indications have specific renewal/duration exceptions as noted in Section I.

    Rheumatoid Arthritis - Response-based continuation

    Rheumatoid Arthritis (RA) continuation/response

    RA response requirements: Disease response demonstrated by improvement in tender/swollen joint counts, reduction in CRP, improved patient global assessment, and/or improvement on disease activity tools (e.g., DAS28 improvement ≥1.2 or ACR20 ≥20% or RAPID3 improvement). Dose escalation may be considered case‑by‑case if initial response then loss of response after minimum maintenance dose received.

    Goal maintenance dosing guidance provided in maintenance section.

    ITP / Evans Syndrome - Response threshold

    Immune Thrombocytopenic Purpura (ITP / Evans Syndrome)

    ITP response: Disease response indicated by achievement and maintenance of platelet count ≥ 30 × 10^9/L and at least doubling of baseline platelet count.platelets >= 30 x10^9/L and >=2x baseline

    TTP - Response indicator

    Thrombotic Thrombocytopenic Purpura (TTP)

    TTP response: Disease response indicated by an increase in ADAMTS13 activity with a reduction in thrombotic risk.increase in ADAMTS13 activity

    Immune Thrombocytopenic Purpura (ITP)

    Covered when disease‑specific response criteria are met

    ITP (Evans Syndrome): Disease response defined as achievement and maintenance of platelet count ≥ 30 × 10^9/L and at least doubling baseline platelet count.platelets >= 30 x10^9/L and >=2x baseline

    Thrombotic Thrombocytopenic Purpura (TTP)

    Covered when disease‑specific response criteria are met

    TTP: Disease response indicated by an increase in ADAMTS13 activity with reduction in thrombotic risk.increase in ADAMTS13 activity

    Multiple Sclerosis (MS)

    Covered when disease‑specific response and monitoring criteria are met

    Multiple Sclerosis: Continuous monitoring demonstrates beneficial response (examples: decreased annualized relapse rate, no new/worsening MRI lesions, and no progression on EDSS/T25‑FW/9‑HPT). Inadequate response defined as ≥1 relapse, ≥2 new MRI lesions, or increased disability over one year.inadequate response: >=1 relapse OR >=2 new MRI lesions OR increased disability over 1 year

    Document adherence and sufficient treatment duration before deeming inadequate response.

    Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Covered when disease control and relapse reduction are demonstrated

    GPA/MPA continuation: Disease control and improvement in signs/symptoms compared to baseline AND decreased frequency of major relapses (reappearance of clinical/lab signs that could lead to organ failure/damage or be life‑threatening).reduced major relapse frequency

    Pemphigus Vulgaris

    Covered when disease control or relapse criteria are met

    Pemphigus Vulgaris continuation: Member receiving tapering or discontinued corticosteroids AND EITHER complete epithelialization and symptom improvement OR no new lesions and healing of established lesions; FOR RELAPSES: prior disease control AND ≥3 new lesions/month not healing within 1 week or extension of established lesions.clinical lesion criteria

    Autoimmune Hemolytic Anemia (AIHA)

    Covered when clinical and laboratory improvement are shown

    AIHA continuation: Improvement in signs/symptoms of anemia AND improvement in lab values (Hgb/Hct), reduced transfusion needs, and/or reduced glucocorticoid use.improved hemoglobin/hematocrit or transfusion reduction

    Systemic Lupus Erythematosus (SLE)

    Covered when clinical benefit is ongoing and standard therapy is continued

    SLE continuation: Member has experienced clinical benefit with the requested agent AND will continue standard SLE therapy (corticosteroids, hydroxychloroquine, azathioprine, methotrexate, mycophenolate, cyclophosphamide).ongoing clinical benefit

    Lupus Nephritis

    Renewal authorization restricted to relapse scenarios

    Lupus Nephritis renewal: Member experienced clinical benefit with the requested agent; prior authorization renewal may be limited to members experiencing a disease relapse (e.g., increased serum creatinine, increased proteinuria, decreased eGFR).objective evidence of relapse required for renewal

    Myasthenia Gravis

    Covered when steroid‑sparing and symptomatic improvement occur

    Myasthenia Gravis continuation: Disease response indicated by decreased daily corticosteroid dose and/or improvement in signs and symptoms compared to baseline.reduced steroid dose or symptom improvement

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Covered when stability or improvement in relapse and resource use is demonstrated

    NMOSD continuation: Stabilization or improvement in any of: decreased acute relapses; reduced hospitalizations; reduction/discontinuation of plasma exchange; reduction/discontinuation of corticosteroids without relapse.any listed improvement

    Antisynthetase Syndrome-Related Interstitial Lung Disease

    Covered when pulmonary and steroid‑sparing responses are demonstrated

    Antisynthetase ILD continuation: Stabilization or improvement in any of: reduction/stabilization of glucocorticoid use; PFT improvement (>10% increase in FVC%, TLC%, or DLCO%) or stabilization (<10% decrease); chest CT improvement (>10% decrease in CT score) or stabilization (<10% increase).PFT/CT percent change thresholds

    Idiopathic Membranous Nephropathy

    Covered when clinical/biochemical improvement or resistance criteria are met

    Idiopathic membranous nephropathy continuation: Member experienced beneficial response with improvement in symptoms and/or objective measures (reduction in proteinuria, improved albumin, stable creatinine/eGFR, decreased anti‑PLA2R) OR has resistant disease following first‑line therapy; AND member has stable eGFR AND will be used with a calcineurin inhibitor if previously treated with rituximab alone.proteinuria/albumin/creatinine/anti‑PLA2R improvement or documented rituximab resistance

    Pediatric Idiopathic Nephrotic Syndrome - Renewal criteria

    Covered for pediatric nephrotic syndrome relapses when prior response documented

    Pediatric nephrotic syndrome continuation: Member previously achieved beneficial response from prior course AND is experiencing recurrent active disease necessitating additional doses (e.g., nephrotic‑range proteinuria dipstick ≥3+ for 3 consecutive days OR UPCR ≥200 mg/mmol on 3 consecutive days).dipstick >=3+ for 3 days OR UPCR >=200 mg/mmol on 3 consecutive days

    Renewal only for relapse scenarios.

    IgG4-Related Disease

    Covered when clinical or steroid‑sparing benefit is demonstrated

    IgG4‑RD continuation: Disease response indicated by reduction in corticosteroid requirement, reduction in flares, or stabilization/improvement in symptoms, imaging, labs, or pathology compared to baseline.any listed improvement

    Indication-specific covered dosing

    Covered when dosing matches indication‑specific regimens listed below

    Oncology pediatric dosing examples: Pediatric aggressive mature B‑cell lymphomas/PTLD: 375 mg/m² IV once weekly for 4–8 doses in a 6‑month period; Pediatric mature B‑cell acute leukemia: induction two doses of 375 mg/m² IV per induction course (Day ‑2 and Day 1) and consolidation one dose per consolidation course; systemic pediatric/oncology regimens up to 750 mg/m² weekly for 4–8 doses where specified.

    Refer to NCCN and product PI for regimen specifics.

    Autoimmune/neurologic dosing examples: MS/NMOSD: 1,000 mg IV on days 1 and 15, repeat every 6 months OR 375 mg/m² IV weekly x4 repeat every 6 months; AIHA/ITP/TTP: 375 mg/m² IV weekly x4 every 6 months OR 1,000 mg IV days 1 and 15 every 6 months; ICI‑toxicities: regimens include 1,000 mg IV days 1 and 15 or 375 mg/m² weekly x4 depending on toxicity; GPA/MPA: induction 375 mg/m² weekly x4 or adults 1,000 mg IV days 1 and 15.

    Multiple equivalent regimens provided; schedule variability noted.

    Transplant/HSCT dosing examples: Hematopoietic cell transplantation conditioning: 375 mg/m² IV one day before transplant then 1,000 mg/m² on days 1, 8, and 15 after transplant; TA‑TMA: 375 mg/m² IV weekly x4 doses; intra‑CSF dosing for CNS disease: 25 mg weekly to twice weekly.

    Renewal and maintenance dosing guidance

    Maintenance dose optimization upon sustained remission for adults

    Adult renewal dose adjustment: Upon renewal after ≥12 months sustained remission and stability, consider incremental dose reduction or interval extension to goal maintenance doses: RA goal maintenance 500 mg IV every 6 months (dose decrease by no more than 500 mg); MS goal maintenance 500 mg IV every 12 months (dose decrease by no more than 500 mg or interval increase by no more than 6 months).>= 12 months sustained remission

    Member‑specific variables apply; documentation required for dose reduction or interval extension.

    Covered Diagnoses (Appendix 1)

    Covered when the patient has one of the following documented diagnoses (ICD‑10 codes) listed in Appendix 1

    Any single matching Appendix 1 ICD‑10 code: Presence of any one ICD‑10 code listed in Appendix 1 supports coverage for rituximab when other policy medical necessity criteria are met.

    Appendix 1 includes multiple oncology, immune, neurologic, and rheumatologic diagnosis codes; use the applicable code on the authorization/claim.

    Diagnosis-based coverage

    Covered when the patient's diagnosis is listed in Appendix 1

    Diagnosis requirement: The claim or authorization must include an ICD‑10‑CM diagnosis code listed in Appendix 1 of the policy excerpt to support coverage for rituximab, in addition to meeting the other indication‑specific criteria.

    Appendix 1 lists covered diagnosis codes; clinical criteria remain required as specified per indication.

    Prior authorization validity varies by indication. Initial authorizations are generally issued for 6 months (180 days) for both oncology and non‑oncology indications unless otherwise specified. Renewals are typically every 6 months (180 days) with oncology renewals permitted up to 2 years total unless an alternate renewal rule applies. The policy explicitly lists indications for which prior authorization validity may NOT be renewed (examples include pediatric B‑cell acute leukemia induction/consolidation, pediatric aggressive mature B‑cell lymphomas induction/consolidation, pediatric Hodgkin lymphoma, KSHV‑associated inflammatory cytokine syndrome, management of most immune checkpoint inhibitor‑related toxicities, hematopoietic cell transplantation, and TA‑TMA). Certain adult oncology pathways have alternate renewal allowances (e.g., some adult B‑cell lymphoma regimens and Adult ALL have specified extended renewal rules).

    For leptomeningeal or intraventricular/intrathecal use, rituximab may be administered via the intra‑CSF route for CNS lymphoma/leptomeningeal disease. The policy notes that interchangeability of rituximab products for intrathecal or intraventricular administration has not been established; the requested product may be approved without substitution and substitution between products for these routes is not assumed.

    Coverage for non‑oncology indications requires that the member is not receiving concurrent CD20‑directed therapy, another biologic agent, or targeted synthetic therapy. Concurrent treatment with these agents is not permitted and may affect approval.

    When rituximab is requested for idiopathic (primary) membranous nephropathy, the policy requires that secondary causes of membranous nephropathy be excluded (examples listed include infections, autoimmune diseases, malignancies, nutritional supplements such as lipoic acid, and NSAIDs). Documentation that alternative etiologies have been ruled out is required before considering coverage under the primary membranous nephropathy criteria.

    Renewal or retreatment for idiopathic membranous nephropathy is contingent on either documented clinical/biochemical improvement from prior rituximab therapy or evidence of resistant disease following appropriate first‑line therapy. The policy specifies that rituximab may be used for treatment‑resistance after prior first‑line regimens (including calcineurin inhibitors or cyclophosphamide plus glucocorticoids) and requires a stable eGFR and, if previously treated with rituximab alone, combination with a calcineurin inhibitor when retreating.

    Dosing schedules and regimens vary substantially by indication and setting. The document emphasizes that dosing and schedules are highly variable and directs providers to reference guideline/regimen sources (for example, NCCN guidance) and the product prescribing information for protocol‑specific timing and doses. Examples across the policy include BSA‑based regimens (e.g., 375 mg/m2 IV weekly x4–8), systemic regimens up to 750 mg/m2 for some oncology uses, and intra‑CSF dosing where applicable.

    In the appendix excerpt and dosing sections shown, the document provides multiple example regimens and states regimen variability, but no additional explicit exclusions are listed in the appendix excerpt itself. Exclusions (where applicable) are defined elsewhere in the full policy rather than in the dosing appendix excerpt.

    The Appendix 1 excerpt lists covered ICD‑10 diagnosis codes supporting rituximab coverage; however, this appendix segment does not include codes beyond those shown. In other words, codes not listed in this Appendix 1 excerpt are not supported by this excerpt for the purpose of authorizations and claims — the full policy or other appendices should be consulted for any additional supported codes.

    Labeling used to define inadequate response in multiple sclerosis is referenced in the policy. Specifically, an inadequate response is defined as ≥1 relapse, ≥2 unequivocally new MRI‑detected lesions, or increased disability on examination over a 1‑year period. Lack of these findings when assessing ongoing need for therapy may support a not‑medically‑necessary determination for continued treatment.

    The appendix excerpt provided does not enumerate specific not‑medically‑necessary (NMN) conditions. For NMN determinations and any conditions considered not medically necessary, reviewers must refer to the main policy text and decision criteria outside of this appendix excerpt.

    Billing, Codes and Quantity Limits

    HCPCS Unit Dosing Limitsmixed
    HCPCS unitsDosing limits and maximum billable units specified per indication (examples: CLL/SLL initial 100 units x1 then 130 units every 7 days x11; Rosai-Dorfman 780 units every 6 months; HCT initial 100 units x1 then 250 units every 7 days x3; immunotherapy-related toxicities 100 units every 7 days x4; RA 200 units every 24 weeks; MS 200 units every 6 months; PV initiation 100 units every 7 days x4 with maintenance 50 units every 6 months).
    HCPCS CodesHCPCS
    J9312Injection, rituximab, 10 mg; 1 billable unit = 10 mg (Rituxan IV only)
    Q5115Injection, rituximab-abbs, biosimilar, (truxima), 10 mg; 1 billable unit = 10 mg
    Q5119Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg; 1 billable unit = 10 mg
    Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg; 1 billable unit = 10 mg
    NDCsNDC
    50242-0051-xxRituxan 100 mg/10 mL single-dose vial for injection
    50242-0053-xxRituxan 500 mg/50 mL single-dose vial for injection
    63459-0103-xxTruxima 100 mg/10 mL single-dose vial for injection
    63459-0104-xxTruxima 500 mg/50 mL single-dose vial for injection
    00069-0238-xxRuxience 100 mg/10 mL single-dose vial for injection
    00069-0249-xxRuxience 500 mg/50 mL single-dose vial for injection
    55513-0224-xxRiabni 100 mg/10 mL single-dose vial for injection
    55513-0326-xxRiabni 500 mg/50 mL single-dose vial for injection
    Referenced Local Coverage Articlesmixed
    A59101CMS Local Coverage Article: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars
    A55639CMS Local Coverage Article: Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
    A56380Palmetto GBA Local Coverage Article: Billing and Coding: Rituximab
    Covered ICD-10 Diagnosis Codes (Appendix 1, partial)ICD-10Covered
    C46.0Kaposi's sarcoma of skin
    C46.1Kaposi's sarcoma of soft tissue
    C46.2Kaposi's sarcoma of palate
    C46.3Kaposi's sarcoma of lymph nodes
    C46.4Kaposi's sarcoma of gastrointestinal sites (partial listing)
    C46.50Kaposi's sarcoma of unspecified lung (partial listing)
    C46.51Kaposi's sarcoma of right lung
    C46.52Kaposi's sarcoma of left lung
    C46.7Kaposi's sarcoma of other sites
    C46.9Kaposi's sarcoma, unspecified
    1–10 of 16
    1/2
    Covered ICD-10 Codes (lymphomas, leukemias, related neoplasms)ICD-10Covered
    C83.59Mantle cell lymphoma, intrathoracic lymph nodes
    C83.70Burkitt lymphoma, unspecified site
    C83.71Burkitt lymphoma, lymph nodes of head, face, and neck
    C83.72Burkitt lymphoma, intrathoracic lymph nodes
    C83.73Burkitt lymphoma, intra-abdominal lymph nodes
    C83.74Burkitt lymphoma, lymph nodes of axilla and upper limb
    C83.75Burkitt lymphoma, lymph nodes of inguinal region and lower limb
    C83.76Burkitt lymphoma, intrapelvic lymph nodes
    C83.78Burkitt lymphoma, spleen
    C83.79Burkitt lymphoma, spleen (variant listing)
    1–10 of 43
    1/5
    Covered ICD-10 Codes (immune-mediated and neurologic conditions)ICD-10Covered
    D59.2Drug-induced nonautoimmune hemolytic anemia
    D59.10Autoimmune hemolytic anemia, unspecified
    D59.11Warm autoimmune hemolytic anemia
    D59.12Cold autoimmune hemolytic anemia
    D59.13Mixed type autoimmune hemolytic anemia
    D59.19Other autoimmune hemolytic anemia
    D69.3Immune thrombocytopenic purpura
    D69.41Evans Syndrome
    D69.42Congenital and hereditary thrombocytopenia purpura
    D69.49Other primary thrombocytopenia
    1–10 of 36
    1/4
    Covered ICD-10-CM Diagnosis Codes (Appendix 1)ICD-10Covered
    M05.461Rheumatoid myopathy with rheumatoid arthritis of right elbow
    M05.462Rheumatoid myopathy with rheumatoid arthritis of left knee
    M05.469Rheumatoid myopathy with rheumatoid arthritis of unspecified knee
    M05.471Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot
    M05.472Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot
    M05.479Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot
    M05.49Rheumatoid myopathy with rheumatoid arthritis of multiple sites
    M05.50Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site
    M05.511Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder
    M05.512Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder
    1–10 of 54
    1/6
    Appendix 1 - Covered Diagnosis CodesICD-10Covered
    N04.1Nephrotic syndrome with focal and segmental glomerular lesions
    N04.2Nephrotic syndrome with diffuse membranous glomerulonephritis
    N04.21Primary membranous nephropathy with nephrotic syndrome
    N04.3Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis
    N04.4Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis
    N04.5Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis
    N04.6Nephrotic syndrome with dense deposit disease
    N04.621Primary membranous nephropathy with isolated proteinuria
    N04.7Nephrotic syndrome with diffuse crescentic glomerulonephritis
    N04.8Nephrotic syndrome with other morphologic changes
    1–10 of 21
    1/3
    Medicare Part B / NCD/LCD reference identifiersmixed
    A55639CMS reference code listed
    A57160CMS reference code listed
    A58582CMS reference code listed
    A59101CMS reference code listed
    A56380CMS reference code listed
    Per-dose or period dosing — Examples of per-dose/period dosing in billable units
    CLL/SLL dosing exampleInitial: 100 billable units x1 dose, then 130 billable units every 7 days x11 doses; Renewal: 130 billable units every 8 weeks.
    Hematopoietic cell transplant (conditioning) dosingInitial pre-transplant: 100 billable units x1 dose; Post-transplant: 250 billable units every 7 days x3 doses.
    Rheumatoid arthritis dosing200 billable units every 24 weeks.
    Multiple sclerosis dosing200 billable units every 6 months.

    Authorization Steps, Documentation and Denial Risks

    Prior Authorization

    Require prior authorization; standard initial validity 6 months

    Prior authorization is required. Initial approvals are typically provided for 6 months (180 days) for both oncology and non‑oncology indications unless otherwise specified; some non‑oncology indications (Pemphigus Vulgaris, Systemic Lupus Erythematosus, Lupus Nephritis) receive an initial PA of 12 months. Oncology PAs may be renewed every 6 months up to 2 years unless otherwise stated; certain pediatric oncology and other listed indications are not renewable per the policy.

    • Standard initial PA: 6 months (180 days) for oncology and non‑oncology unless specified [[see cited chunks]]
    • Select non‑oncology: initial 12 months for PV, SLE, LN
    • Oncology renewals: every 6 months up to 2 years unless specified; some oncology indications non‑renewable
    Prior Authorization

    Must trial specified biosimilars before other rituximab products

    Providers must document that the member has had a contraindication, intolerance, or therapeutic failure to each of the three named rituximab biosimilars—Riabni, Ruxience, AND Truxima—before another rituximab product will be considered.

    Initial Therapy — Eligibility and Dosing

    Renewal and Maintenance Therapy

    Required Prior Therapies and Step Rules

    StepRequirement
    1
    Prior authorization step 1: Refer to specific step requirements below (biosimilar trial, indication-specific prior therapy, or documented intolerance/contraindication as applicable).
    Coverage requirementDetails
    Biosimilar trial requirement
    Member must have a contraindication, intolerance, or failure to Riabni®, Ruxience®, AND Truxima® prior to consideration of another rituximab product.
    RequirementDetails / Exception
    RA csDMARD trial requirement
    Physician must document baseline disease severity and member must have tried and failed at least a 3-month trial with one conventional synthetic DMARD (e.g., methotrexate) OR be already established on biologic/targeted therapy; rituximab is used with methotrexate unless contraindicated.
    RequirementApplicable indications / Notes
    Standard first-line therapy trial required
    For several non-oncology indications (e.g., antisynthetase ILD, myasthenia gravis MuSK-positive, idiopathic membranous nephropathy), prior trials and failure of standard first-line therapies (glucocorticoids and/or immunosuppressive agents such as azathioprine, mycophenolate, calcineurin inhibitors, etc.) are required unless contraindicated or intolerant.
    RequirementDocumentation required
    Prior first-line therapy history required
    For use of rituximab as second-line therapy (e.g., idiopathic membranous nephropathy), providers must document prior first-line therapy history and demonstrate resistant disease or relapse after first-line agents; secondary causes must be excluded and stable eGFR documented where required.
    RequirementPolicy reference / Action
    Dose escalation criteria referenced
    Policy notes that dose escalation or increased dosing frequency for certain indications should follow referenced criteria; upon renewal after ≥12 months sustained remission consider incremental dose reduction/interval extension to maintenance goals per indication — dose changes require meeting renewal conditions and documented stability.

    Per-Dose and Period Quantity Limits

    rituximab — per-indication HCPCS billable unit limits and examples
    Per‑indication HCPCS unit examplesVarious limits specified (examples include CLL/SLL: 100 units x1 then 130 units q7d x11; Rosai‑Dorfman: 780 units every 6 months; HCT: 100 unit pre‑transplant then 250 units q7d x3 post‑transplant)
    Non‑oncology example (general)Selected non‑oncology indications (AIHA, SLE/LN, MG, NMOSD, antisynthetase ILD, membranous nephropathy, pediatric nephrotic syndrome): 400 billable units every 6 months
    Pemphigus maintenance examplePemphigus vulgaris maintenance: 50 billable units every 6 months
    Rituximab (non-oncology indications listed) — 400 billable units example
    Standard non‑oncology per‑period limit400 billable units every 6 months for listed non‑oncology indications
    Indications included

    Administration Setting and Route Considerations

    Note

    Intrathecal/intraventricular routes: interchangeability not established

    For leptomeningeal disease requiring intrathecal or intraventricular administration, note that interchangeability of rituximab products for these routes has not been established; the requested product may be approved without substitution.

    • Intrathecal/intraventricular administration may be required for leptomeningeal disease
    • Interchangeability for intra‑CSF routes is not established—product substitution may not occur
    Documentation Required

    Specify administration route (IV vs intra‑CSF) and site on PA

    Administration routes include systemic IV and intra‑CSF (intrathecal/intraventricular) depending on indication; follow the regimen protocol and document the planned site/route in the PA.

    • Specify systemic IV vs intra‑CSF route and planned dosing schedule when requesting PA
    • Site‑of‑care (infusion center vs hospital outpatient) should be documented as clinically indicated

    Biosimilars, Product Substitution and Identifiers

    Note

    Covered rituximab brands listed

    Rituximab brands covered in the policy include Riabni, Rituxan, Ruxience, and Truxima; coverage applies across the listed products subject to step/PA rules.

    • Covered brands: Riabni®, Rituxan®, Ruxience®, Truxima®
    Prior Authorization

    Document contraindication/intolerance/failure to all three named biosimilars before other products

    Providers must document that the member has a contraindication, intolerance, or failure to Riabni, Ruxience, AND Truxima prior to consideration of another rituximab product; this requirement is explicit in the policy.

    • Explicit three‑biosimilar trial/failure requirement before other rituximab products are considered

    Background and Clinical Context

    Rituximab is an anti‑CD20 monoclonal antibody used across a range of oncology and non‑oncology indications. The policy lists covered products including branded and biosimilar forms (examples: Riabni®, Rituxan®, Ruxience®, Truxima®) and defines indication‑specific authorization, dosing, renewal, and documentation requirements to support medical necessity determinations.

    Key Definitions and Diagnostic Criteria

    Rituximab (brand listing) — brands covered
    Brands/biosimilars coveredRiabni, Rituxan, Ruxience, Truxima (IV/intrathecal/intraventricular)
    HCPCS codes referencedJ9312 (rituximab) and biosimilar Q‑codes Q5115, Q5119, Q5123
    NDC listingsMultiple NDCs listed for Rituxan and biosimilars in Appendix (see coding section)
    HBV screening — Testing and monitoring prior to initiating rituximab
    HBV screening tests requiredTesting for HBsAg and anti‑HBc prior to initiating rituximab
    Monitoring planMembers with evidence of current or prior HBV infection will be monitored for HBV reactivation during treatment

    References, Appendices and Regulatory Guidance

    Note

    References only (no PA rules)

    This references list segment contains citations and does not impose provider actions beyond using the references to support documentation where appropriate.

    Note

    Reference‑only section

    Placeholder reference-only callout; no provider actions specified in this excerpt.

    Medicare Part B / NCD/LCD reference identifiersmixed
    A55639CMS reference code listed
    A57160CMS reference code listed
    A58582CMS reference code listed
    A59101CMS reference code listed
    A56380CMS reference code listed
    HCPCS Codes referenced in appendixHCPCS
    J9312Injection, rituximab, 10 mg; 1 billable unit = 10 mg (Rituxan IV only)
    Q5115Injection, rituximab-abbs, biosimilar, (truxima), 10 mg; 1 billable unit = 10 mg
    Q5119Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg; 1 billable unit = 10 mg
    Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg; 1 billable unit = 10 mg
    NDC entries for reference products and biosimilarsNDC
    50242-0051-xxRituxan 100 mg/10 mL single-dose vial for injection
    50242-0053-xxRituxan 500 mg/50 mL single-dose vial for injection
    63459-0103-xxTruxima 100 mg/10 mL single-dose vial for injection
    63459-0104-xxTruxima 500 mg/50 mL single-dose vial for injection
    00069-0238-xxRuxience 100 mg/10 mL single-dose vial for injection
    00069-0249-xxRuxience 500 mg/50 mL single-dose vial for injection
    55513-0224-xxRiabni 100 mg/10 mL single-dose vial for injection
    55513-0326-xxRiabni 500 mg/50 mL single-dose vial for injection
    Policy Summary
    PayerViva Health
    PolicyRituximab (Riabni, Rituxan, Ruxience, Truxima) Coverage Criteria
    Policy CodePolicy IC-0109
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with an eligible Appendix 1 ICD-10 diagnosis and document prior trials, dosing regimen, and HBV screening per policy.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling, Codes and Quantity LimitsAuthorization Steps, Documentation and Denial RisksInitial Therapy — Eligibility and DosingRenewal and Maintenance TherapyRequired Prior Therapies and Step RulesPer-Dose and Period Quantity LimitsAdministration Setting and Route ConsiderationsBiosimilars, Product Substitution and IdentifiersBackground and Clinical ContextKey Definitions and Diagnostic CriteriaReferences, Appendices and Regulatory Guidance
    CNS cancers dosing: Initial: 190 billable units every 7 days x8 doses. Renewal: 100 billable units every 28 days.

    Intrathecal/intraventricular dosing for leptomeningeal disease noted separately.

    Hairy Cell Leukemia: 100 billable units every 7 days x8 doses, then 100 units every 14 days x8 doses, then 100 units every 28 days x4 doses.
    Immunotherapy‑related toxicities dosing: Myositis/encephalitis/hemolytic anemia/thrombocytopenia/AKI: 100 billable units every 7 days x4 doses; Bullous dermatitis/pemphigoid: 100 units every 14 days x2 doses then 50 units at months 12 & 18; Myasthenia gravis related to ICI: 130 units every 7 days x4 doses.
    TA‑TMA dosing: 100 billable units every 7 days x4 doses.
    HCT conditioning dosing: Initial dose: 100 billable units x1 before transplant; Subsequent: 250 billable units every 7 days x3 doses after transplant.
    Rheumatoid arthritis and MS dosing: Rheumatoid arthritis: 200 billable units every 24 weeks. Multiple sclerosis (relapsing forms): 200 billable units every 6 months.
    Pemphigus vulgaris dosing: Initiation: 100 billable units every 7 days x4 doses in a 12‑month period; Maintenance: 50 billable units every 6 months.
    General non‑oncology periodic dosing: Other non‑oncology indications (e.g., AIHA, SLE/LN, MG, NMOSD, antisynthetase ILD, membranous nephropathy, pediatric nephrotic syndrome): 400 billable units every 6 months unless indication‑specific alternative dosing noted.
    CLL/SLL clinical use: Use per specified combinations and mutation status with restrictions (del(17p)/TP53 guidance, first‑line and subsequent therapy options, and use in Richter transformation as described).

    Refer to CLL/SLL indication node for regimen specifics.

    Hematopoietic cell transplantation (conditioning): Used as conditioning for allogeneic transplant as part of a non‑myeloablative regimen in combination with cyclophosphamide and fludarabine.
    cGVHD: Member is post‑allogeneic HCT (generally ≥3 months), used as additional therapy with systemic corticosteroids, and steroid‑refractory to first‑line therapy options.
    Selected non‑oncology autoimmune and rare disease examples: Examples include: Pemphigus vulgaris (diagnostic confirmation and moderate‑severe disease with specified induction/maintenance dosing); Wiskott‑Aldrich pre‑therapy use; GPA/MPA induction and maintenance; TA‑TMA high‑risk post‑HSCT; AIHA criteria; SLE without active LN with prior therapy failures or contraindications; Lupus nephritis class III/IV/V with biopsy confirmation and background immunosuppression; NMOSD seropositive or seronegative/unknown pathways with core clinical characteristics and MRI; antisynthetase syndrome‑related ILD with antibody positivity and objective PFT/CT baseline and failure of prior therapy; idiopathic membranous nephropathy with excluded secondary causes and specified high‑risk features.

    Representative selection; refer to each indication node for full criteria.

    Acute kidney injury from ICI: Stage 3 AKI/elevated creatinine related to immunotherapy AND toxicity remains > stage 2 after 4–6 weeks of corticosteroids OR creatinine increases during corticosteroid taper or once off steroids.
    Myositis/myasthenia gravis related to ICI: Used for significant dysphagia, life‑threatening situations, or steroid‑refractory myositis; for myasthenia gravis used as additional therapy for severe (G3–4) disease refractory to plasmapheresis or IVIG.
    Other indication dosing: Pediatric Hodgkin lymphoma, complications of transplanted solid organ, antisynthetase ILD, pediatric idiopathic nephrotic syndrome, idiopathic membranous nephropathy, and pre‑gene therapy timing (single 375 mg/m² IV ≈22 days prior to etuvetidigene autotemcel) with specified timing/doses per indication.
    Pemphigus vulgaris initiation/maintenance
    Initiation: 100 billable units every 7 days x4 doses in a 12-month period; Maintenance: 50 billable units every 6 months.
    Random urine protein to creatinine ratio (rUPCR)
    rUPCR threshold for TA-TMA>= 1
    Supporting TA-TMA high-risk featureUsed as one of the criteria to define high‑risk TA‑TMA for post‑HSCT patients
    ApplicationPresence of rUPCR >=1 contributes to meeting coverage criteria for TA‑TMA indication
    LDH — Laboratory threshold
    LDH threshold>= 2 x ULN
    ContextElevated LDH ≥2×ULN is listed as a high‑risk feature for TA‑TMA in post‑HSCT members
    Use in decision-makingLDH ≥2×ULN supports classification as high‑risk TA‑TMA and meeting coverage criteria
    Platelet count for increased bleeding risk (ITP)
    Platelet count threshold for bleeding risk (ITP)< 30,000/mm3 (platelets < 30 × 10^9/L)
    Prior therapy requirementMember must have failed or be intolerant to corticosteroids prior to rituximab for ITP/Evans
    Timing windowPlatelet count must be documented within the previous 28 days
    ITP platelet response — threshold for response
    ITP platelet response criterionAchievement and maintenance of platelet count ≥30 × 10^9/L and at least doubling of baseline platelet count
    PurposeUsed to document treatment response for continuation/renewal in ITP/Evans Syndrome
    MeasurementResponse assessed by serial platelet counts compared to baseline
    Pulmonary function/CT improvement/stabilization thresholds
    PFT improvement threshold>10% increase in FVC%, TLC%, or DLCO%
    PFT stabilization threshold<10% decrease in FVC%, TLC%, or DLCO% (stabilization)
    Chest CT thresholdsImprovement: >10% decrease in CT score; Stabilization: <10% increase in CT score
    N/A placeholder from inventory
    N/A placeholderN/A
    Appendix contextNo applicable numeric threshold provided in this inventory placeholder; refer to specific criteria elsewhere in policy for applicable measures
    Document guidanceThis entry is a placeholder and not a clinical threshold
    Document chunk range (coding section)
    Appendix 1 chunk range180-199
    Content includedAppendix 1 lists covered ICD-10 diagnosis codes (multiple lymphoma, leukemia, immune, neurologic, and rheumatoid disease codes) relevant to authorization and claims
    Clinical useAn ICD-10-CM code from this appendix must be submitted with authorizations/claims to support coverage per policy
    • Member must have contraindication, intolerance, or failure to Riabni®, Ruxience®, AND Truxima® prior to consideration of another rituximab product
    Documentation Required

    Include prior therapy history, objective severity, and combination rationale

    Prior authorization requests must include documentation of prior therapy trials/failures, objective measures of disease severity, and rationale for any combination therapy (e.g., RA requires methotrexate unless contraindicated).

    • Document prior treatment trials and failures (e.g., csDMARD trial for RA, prior corticosteroid/immunosuppressive trials for SLE/LN)
    • Provide objective disease severity assessments (e.g., PDAI for pemphigus, MRI for MS)
    • If requesting combination therapy, include rationale and supporting evidence per prescribing information
    Prior Authorization

    Renew only if criteria, duration limits, and safety are satisfied

    Renewal of prior authorization is allowed only if the member continues to meet the universal and indication‑specific criteria, duration limits have not been exceeded, and there is absence of unacceptable toxicity.

    • Member must continue to meet universal and indication‑specific criteria
    • Duration limits per Section I must not be exceeded
    • No unacceptable toxicity (examples listed in policy) should be present
    Prior Authorization

    Specify indication‑specific dosing regimen on the PA

    The prior authorization must specify the indication‑specific dosing regimen requested (examples include 375 mg/m² IV weekly x4–8 for many indications); PA approvals should match the indicated regimen and schedule.

    • State the exact regimen (e.g., 375 mg/m² IV weekly x4–8; intra‑CSF dosing where applicable)
    • Systemic IV dosing options and renewal schedules (e.g., 375 mg/m² IV once weekly for 4 doses per 6 months) should be reflected in the PA
    Billing Rule

    Include HCPCS J9312, biosimilar Q‑codes, and relevant NDCs

    Use the listed billing codes and product identifiers when requesting authorization and for claims: HCPCS J9312 and biosimilar Q‑codes Q5115, Q5119, Q5123, and include the appropriate NDC for the product supplied.

    • HCPCS: J9312; Q5115; Q5119; Q5123
    • Include NDC for the specific product vial (examples shown in policy Appendix)
    Note

    References (no PA rules in this excerpt)

    This section is reference material only and does not impose prior authorization rules by itself.

    Note

    CMS local coverage articles cited — may affect billing & PA

    CMS Local Coverage Articles relevant to rituximab billing, coding, and off‑label use are cited and may inform prior authorization and reimbursement determinations; providers should follow those LCAs where applicable.

    • Local Coverage Articles cited include A59101, A55639, A56380 (see policy references)
    Note

    PA may be applied based on NQTL factors (indication, safety, cost)

    The NQTL checklist indicates prior authorization may be applied because of indication, safety/efficacy, and cost considerations; PA may therefore be required for certain uses.

    • Factors considered for PA: indication, safety/efficacy, and drug cost (per NQTL checklist)
    Prior Authorization

    Cite a covered ICD‑10 diagnosis from Appendix 1 on PA requests

    Prior authorization requests must include an eligible ICD‑10 diagnosis from the policy’s covered‑diagnosis list to establish medical necessity for rituximab.

    • Cite one of the Appendix 1 ICD‑10 codes that corresponds to the covered indication when submitting PA and claims
    Documentation Required

    Use Appendix 1 diagnosis codes to support authorization/claims

    Appendix 1 lists the covered ICD‑10 diagnosis codes; include one of these codes on the authorization and claim to support coverage.

    • Use the specific ICD‑10‑CM code from Appendix 1 that matches the member’s diagnosis
    Billing Rule

    Comply with Medicare Part B NCDs/LCDs and CMS guidance

    For Medicare Part B claims, follow CMS guidance and applicable NCDs/LCDs; compliance with local coverage determinations and articles is required where applicable.

    • Medicare Part B coverage must follow the Medicare Benefit Policy Manual and applicable NCDs/LCDs/LCAs
    Step Therapy

    Step requirement: trial/intolerance/failure of Riabni, Ruxience, and Truxima

    Step therapy requires that the member trial and have contraindication/intolerance or failure to the three named biosimilars—Riabni, Ruxience, and Truxima—before coverage of another rituximab product will be considered.

    • Must trial Riabni, Ruxience, AND Truxima (or document contraindication/intolerance/failure) prior to other rituximab products
    Step Therapy

    Step therapy: prior trial/failure of specified conventional therapies

    Step therapy also requires prior trial and failure of specified conventional therapies for some indications (e.g., RA requires ≥3 months of one csDMARD unless the member is already on biologic/targeted therapy).

    • RA: failed ≥3‑month trial of one csDMARD or already established on biologic/targeted therapy
    • SLE: inadequate response/intolerance to hydroxychloroquine plus a corticosteroid or immunosuppressive agent as specified
    Step Therapy

    Require prior trials/failures of standard therapies for non‑oncology uses

    For several non‑oncology indications, coverage requires prior trials and failure of standard therapies (e.g., glucocorticoids, azathioprine, mycophenolate, calcineurin inhibitors) unless contraindicated or intolerant.

    • Document trials and failures of standard first‑line agents or provide reason for contraindication/intolerance
    Documentation Required

    Document prior first‑line therapy and eGFR stability for membranous nephropathy

    For idiopathic membranous nephropathy, document prior first‑line therapy history; rituximab may be considered for resistant disease following first‑line therapy and documentation of stable eGFR and prior treatments is required.

    • Confirm secondary causes ruled out and provide prior first‑line therapy details (ACEi/ARB response, calcineurin inhibitor use, prior rituximab exposure)
    • Document stable eGFR if considering retreatment
    Note

    Guideline citations provided to inform sequencing (informational)

    Guideline citations (e.g., EULAR, British Society for Rheumatology, NCCN) are provided as informational sources to support sequencing and documentation but do not by themselves create additional PA rules in this excerpt.

    • Use referenced guidelines and NCCN order templates for regimen details and documentation as needed
    Documentation Required

    HBV screening required; document results and monitoring plan

    Document that the member was screened for hepatitis B (HBsAg and anti‑HBc) prior to initiating rituximab and include a plan for monitoring for HBV reactivation if there is evidence of prior or current infection.

    • Include HBsAg and anti‑HBc testing results and monitoring plan for HBV reactivation in the medical record/PA
    Documentation Required

    Confirm no live vaccines within 28 days and document avoidance plan

    Confirm and document that the member has not received a live vaccine within 28 days prior to starting treatment and include a plan to avoid live vaccines while on therapy.

    • Provider must attest that no live vaccines were given within 28 days prior to initiation and document plan to avoid live vaccines during treatment
    Documentation Required

    Include diagnosis confirmation and objective severity measures

    Required documentation varies by indication and includes diagnosis confirmation (e.g., biopsy, MRI), objective disease severity measures (e.g., PDAI for pemphigus), prior treatment history and failures, and supporting laboratory/biopsy reports.

    • Provide histopathology/DIF/IIF for pemphigus, MRI reports for MS, kidney biopsy for LN, and other indication‑specific diagnostic tests
    • Include prior treatment trials and evidence of failure or intolerance
    Documentation Required

    Document antibody status, baseline measures, prior therapy, and monitoring plans

    Providers must document diagnosis‑specific criteria such as antibody positivity (e.g., MuSK, AQP4, antisynthetase antibodies), baseline disease measures (PFTs, chest CT, proteinuria/eGFR), prior therapy trials/failures, and monitoring plans.

    • Document antibody test results (MuSK, AQP4, antisynthetase) when applicable
    • Provide baseline PFTs, chest CT, UPCR/proteinuria, eGFR, and steroid/immunosuppressive use as indicated
    Documentation Required

    Provide baseline and follow‑up objective response measures for renewal

    For renewal requests, include baseline and follow‑up objective measures of disease activity (e.g., platelet counts for ITP, ADAMTS13 activity for TTP, imaging or lab improvements) to demonstrate treatment response.

    • ITP: platelet counts showing response (≥30 ×10^9/L and ≥2× baseline)
    • TTP: ADAMTS13 activity improvement and reduced thrombotic risk
    • MS/ILD/SLE: imaging or pulmonary function test changes as applicable
    Documentation Required

    Require ≥12 months sustained remission/stability to support dose reduction at renewal

    If requesting dose reduction or interval extension at renewal, documentation must show ≥12 months sustained remission and stability at the current dose/frequency for adults.

    • At least 12 months sustained remission required before considering dose reduction/interval extension
    • Specify proposed maintenance goal doses (e.g., RA goal 500 mg IV q6 months; MS goal 500 mg IV q12 months)
    Note

    NQTL factors considered in PA design

    The NQTL checklist documents factors considered (indication, safety/efficacy, misuse/abuse potential, cost) when designing and applying prior authorization to rituximab.

    Documentation Required

    Include Appendix 1 ICD‑10 code with authorization/claim

    Submit the applicable ICD‑10 diagnosis code from Appendix 1 with the authorization/claim to support medical necessity for rituximab.

    • Ensure the claim/PA contains an Appendix 1 ICD‑10 code that matches the requested indication
    Denial Risk

    Renewal may be denied for exceeded duration or unacceptable toxicity

    Renewal may be denied if duration limits are exceeded or if unacceptable toxicity is present (examples include severe infusion reactions, TLS, PML, HBV reactivation, serious infections, cardiac events, renal toxicity, bowel obstruction/perforation).

    • Document absence of unacceptable toxicities when requesting renewal
    • Be aware listed toxicities can trigger denial
    Denial Risk

    Risk of denial for insufficient demonstrated treatment response

    A renewal or continuation request may be denied if there is insufficient documentation of adequate treatment response or adherence (e.g., for MS, inadequate response is defined as ≥1 relapse, ≥2 new MRI lesions, or increased disability over one year).

    • Provide documentation of adherence and objective response before renewal
    • For MS, document absence of the inadequate response criteria if requesting continued therapy
    Prior Authorization

    Dose reduction/interval extension only after ≥12 months sustained remission

    Dose reduction or interval extension is allowed only on renewal after at least 12 months of sustained remission and documented stability at current dose and frequency for adults; failure to meet these renewal conditions may affect coverage.

    • Do not request dose reduction/interval extension without ≥12 months documented remission and stability
    Billing Rule

    Billing/coding reference risks from cited CMS LCAs

    Billing and coding local coverage articles for rituximab and off‑label uses are referenced; incorrect billing/coding that does not follow those articles may affect reimbursement or trigger denials.

    • See CMS LCAs (A59101, A55639, A56380) cited in references for billing/coding guidance
    Denial Risk

    Risk of denial for diagnosis code mismatch (use Appendix 1 codes)

    Claims lacking a supported ICD‑10 diagnosis from the covered‑diagnosis appendix (Appendix 1) may be denied; ensure the claim/authorization includes an applicable covered code.

    • Verify the submitted ICD‑10 code is listed in Appendix 1 for the requested indication
    Billing Rule

    Medicare claims must follow NCDs/LCDs/LCAs

    Where Medicare Part B applies, claims must comply with applicable Medicare NCDs, LCDs, and LCAs; noncompliance may affect Medicare coverage determinations.

    • Medicare claims must follow the Medicare Benefit Policy Manual and applicable NCD/LCD/LCA guidance
    Applies to AIHA, SLE/LN, Myasthenia Gravis, NMOSD, Antisynthetase ILD, Idiopathic Membranous Nephropathy, Pediatric Idiopathic Nephrotic Syndrome
    Usage notePolicy lists this as the typical quantity limit for 'all other non‑oncology indications' in the dosing table
    Rituximab (Pemphigus Vulgaris maintenance) — 50 billable units
    Pemphigus Vulgaris maintenance limit50 billable units every 6 months (maintenance)
    Initiation vs maintenanceInitiation: 100 billable units every 7 days x4 doses in a 12‑month period; Maintenance: 50 units q6 months
    ContextUsed to define quantity limits for PV maintenance dosing in policy
    Billing Rule

    Use correct HCPCS/NDC for billed product; site‑of‑care may affect billing

    Billing code and HCPCS guidance are provided in the policy; ensure the correct HCPCS and NDC are used for the product administered—site‑of‑care is not restricted by these chunks but may affect billing rules.

    • Confirm HCPCS and NDC on claim match the administered product and vial size
    • Site‑of‑care billing considerations may vary by payer/Medicare rules
    Note
    Billing Rule

    HCPCS Q‑codes and NDCs for biosimilars and reference product

    HCPCS Q‑codes Q5115, Q5119, Q5123 are listed for biosimilars alongside J9312 for reference rituximab; NDC listings for each product and vial size are provided and should be used for product identification in PA and claims.

    • HCPCS: J9312 (reference), Q5115 (Truxima), Q5119 (Ruxience), Q5123 (Riabni)
    • NDC examples provided for 100 mg and 500 mg vials of each product
    Billing Rule

    Use listed biosimilar HCPCS Q‑codes and NDCs for claims

    Additional HCPCS Q‑codes and NDC entries for the biosimilars are listed in the policy Appendix; use these for accurate product identification on authorizations and claims.

    Note
    Note

    Biosimilar comparison studies cited; no explicit substitution rule in excerpt

    The policy cites analytical and clinical comparisons of biosimilars to the rituximab reference product but does not state an explicit payer substitution or preference rule in this excerpt.

    • Biosimilar comparability studies are referenced; no explicit automatic substitution policy noted here
    Vaccination noteConfirm member has not received a live vaccine within 28 days prior to starting therapy
    High-risk TA-TMA — listed high-risk features
    TA‑TMA high‑risk criteria (examples)High‑risk features include rUPCR ≥ 1; elevated serum sC5b‑9 > ULN; LDH ≥ 2 × ULN; concurrent grade II–IV acute GVHD; concurrent infections; TA‑TMA‑related organ dysfunction
    ApplicationPresence of any one high‑risk feature defines high‑risk TA‑TMA in policy
    PopulationApplies to adult and pediatric post‑HSCT members
    Pemphigus diagnostic confirmation — biopsy/DIF/autoantibody requirements
    Pemphigus confirmation requirementsDiagnosis requires clinical features + histopathologic confirmation by biopsy + positive direct immunofluorescence (DIF) OR presence of autoantibodies by IIF/ELISA
    Severity assessmentMember must have moderate to severe disease assessed with objective tool (e.g., PDAI, PSS, ABSIS)
    Dosing exampleInitiation: 100 units q7d x4 doses; Maintenance: 50 units q6 months
    Core clinical characteristics of NMOSD
    Core NMOSD clinical characteristicsAcute optic neuritis; acute myelitis; acute area postrema syndrome; acute brainstem syndrome; symptomatic narcolepsy or diencephalic syndrome; acute cerebral syndrome
    RoleAt least one core characteristic required for AQP4‑seropositive pathway; two (with specified features) for seronegative pathway
    MRI linkageSome core characteristics require corresponding typical MRI findings per policy
    Typical MRI findings in NMOSD
    Typical NMOSD MRI findings (examples)LETM (myelitis ≥3 vertebral segments), optic nerve lesions ≥ half optic nerve length or involving chiasm, dorsal medulla (area postrema) lesion, periependymal brainstem/diencephalic/cerebral patterns
    UseRequired for seronegative/unknown AQP4‑IgG pathway to establish NMOSD diagnosis per policy
    Imaging modalitiesT2 and T1/Gd MRI sequences referenced for lesion characterization
    ITP response — policy definition
    ITP response definitionAchievement and maintenance of platelet count ≥ 30 × 10^9/L and at least doubling baseline platelet count
    PurposeDefines clinical response used for renewal/continuation decisions in ITP/Evans syndrome
    Reference windowPlatelet count within prior 28 days used in criteria context
    TTP response — policy definition
    TTP response definitionIncrease in ADAMTS13 activity with reduction in thrombotic risk
    ContextUsed to document disease response for TTP in renewal/continuation criteria
    Combination therapy noteRituximab used in combination with corticosteroids and therapeutic plasma exchange where indicated
    Chemotherapy regimen abbreviations (COP/COPDAM/CYM/CYVE/RICE)
    Chemotherapy regimen abbreviationsCOP = Cyclophosphamide, Oncovin (vincristine), Prednisone; COPDAM = Cyclophosphamide, Oncovin, Prednisolone, Adriamycin, Methotrexate; CYM = Cytarabine, Methotrexate; CYVE = Cytarabine, Vepesid; RICE = Rituximab, Ifosfamide, Carboplatin, Etoposide
    UseAbbreviations used in oncology dosing/regimen descriptions throughout policy
    ReferenceNCCN and literature references cited in policy reference section
    rituximab biosimilars — analytical and clinical similarity studies cited
    Biosimilar comparability evidenceAnalytical and clinical similarity studies cited for biosimilars (e.g., CT‑P10, PF‑05280586, others) supporting comparability to reference rituximab
    ImplicationPolicy lists biosimilar studies but does not prescribe substitution rules beyond step requirements
    Selected referencesMultiple randomized and PK studies are referenced in the policy reference list
    Covered diagnosis codes (Appendix 1) — reference to ICD‑10 codes
    Appendix 1 purposeLists covered ICD‑10‑CM diagnosis codes that support coverage when policy criteria are met
    Examples includedMultiple lymphoma, leukemia, immune‑mediated, neurologic, and rheumatoid disease codes are present in Appendix 1 excerpts
    Provider requirementAuthorization/claim should include an eligible Appendix 1 ICD‑10 code per policy guidance